3 completed, 3 recruiting, 1 active not recruiting, 1 withdrawn. 4 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow agenT-797: new trials by email Literature Review of agenT-797 trials Research Report on agenT-797
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Recruiting | University of Wisconsin, Madison | 22 | 2026-11-01 | 2026-11-12 |
| BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases Balstilimab (BAL), Botensilimab (BOT), agenT-797 - Colorectal Cancer Metastatic | Phase 2 | Recruiting | Darren Sigal, MD | 17 | 2026-06-10 | 2026-08-10 |
| A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure agenT-797, Placebo, Standard of Care (SOC) - Pneumonia | Phase 2 | Recruiting | MiNK Therapeutics | 90 | 2026-05-26 | 2026-06-26 |
| Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia Nogapendekin alfa inbakicept (NAI), agenT-797 - Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer AgenT-797, Botensilimab, Balstilimab - Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-02-01 | 2026-05-15 |
| A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors agenT-797, Approved ICIs - Tumor, Solid | Phase 1 | Completed | MiNK Therapeutics | 34 | 2022-01-28 | 2024-04-24 |
| agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma agenT-797 - Relapsed/Refractory Multiple Myeloma | Phase 1 | Completed | MiNK Therapeutics | 13 | 2021-03-29 | 2023-06-06 |
| A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS agenT-797 - Respiratory Distress Syndrome, Adult | Phase 1 | Completed | MiNK Therapeutics | 20 | 2020-09-21 | 2025-12-30 |
Respiratory Distress Syndrome (2) · Adenocarcinoma Of Esophagus (1) · Colorectal Neoplasms (1) · Community-Acquired Pneumonia (1) · Critical Illness (1) · Esophageal Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphopenia (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Pneumonia (1) · Respiratory Insufficiency (1) · Sepsis (1)
MiNK Therapeutics (4) · Darren Sigal, MD (1) · ImmunityBio, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · University of Wisconsin, Madison (1)
United States (7) · Ukraine (1)
Hongtau Liu, MD, PhD (1) · Jayson Garmizo (1) · Yelena Janjigian, MD (1)